The ophthalmic pharmaceutical company TearClear has named Robert J. Dempsey as CEO.
“We are emerging as a global leader in treating glaucoma and inflammatory conditions such as dry eye disease,” Dempsey said in a company press release. “TearClear is producing medications that address a critical unmet need for preservative-free eye drops, and I’m excited to lead this effort with the team.”
Dempsey has more than 20 years of ophthalmic pharmaceutical industry experience, previously serving as the global head of ophthalmology at Shire, and he was responsible for one of
Uncategorized